AI Designs Working T-Cell Receptors That Could Transform Immunotherapy Screening

Artificial intelligence has now moved from predicting the shapes of proteins to designing the molecular sensors of the human immune system. In a study published in Genome Biology, a team of researchers from Tencent’s AI for Life Sciences Lab, City University of Hong Kong, The University of Hong Kong, Xijing Hospital of Digestive Diseases, Harvard Medical School, Monash University, and collaborators unveiled a generative model called the Epitope-Receptor-Transformer, or ERTransformer. The system generates candidate T-cell receptor sequences tailored to recognize specific molecular targets, and remarkably, laboratory tests showed that some of these artificial receptors can activate T cells as strongly as, or even more strongly than, the receptors that nature itself produced. The work, led by Jiannan Yang, Bing He, Lei Guan, Shouzhi Chen, and Yu Zhao as co-first authors, with corresponding authors including Jianhua Yao, Qingpeng Zhang, and Ting Li, points toward a future in which the search for therapeutic T-cell receptors begins on a computer rather than at the laboratory bench.

To understand why this matters, it helps to consider how T cells work. Each T cell in the body carries a receptor, known as a T-cell receptor or TCR, that recognizes fragments of foreign or abnormal proteins displayed on the surface of other cells. These fragments, called epitopes, are presented by human leukocyte antigen molecules, or HLAs, forming a peptide-HLA complex that the TCR must read with exquisite specificity. The portion of the receptor that does most of this reading is a loop called the CDR3 region on the beta chain of the receptor. Because the DNA sequences encoding CDR3 loops are assembled randomly during T-cell development, the human body can theoretically produce an astronomically large repertoire of receptors, allowing it to recognize nearly any pathogen or tumor marker it might encounter.

The problem for immunotherapy developers is that finding the right receptor for a given target is extraordinarily difficult. When a patient’s tumor displays a particular peptide on its HLA molecules, researchers want to identify or engineer TCRs that will bind that peptide-HLA complex specifically, so that engineered T cells can home in on the cancer. Today, that process depends heavily on laborious and expensive experimental screening: collecting T cells that happen to respond to the target, sequencing their receptors, cloning candidates, and testing them one by one. The sheer scale of possible CDR3 sequences means that even large screens sample only a vanishingly small corner of the search space, and promising receptors may be missed entirely. This bottleneck is precisely what the ERTransformer was designed to relieve.

The architecture of the new model rests on two pre-trained transformer networks, the same class of deep learning architecture that underlies modern large language models. The first component, EpitopeBERT, was trained on approximately 1.9 million epitope sequences, allowing it to internalize the statistical grammar of the peptide fragments that the immune system encounters. The second, ReceptorBERT, was trained on roughly 33.1 million TCR sequences, giving it a deep understanding of the structural and compositional constraints that govern which receptor loops are biologically plausible. By combining these two pre-trained encoders, ERTransformer can be conditioned on a specific epitope and then generate candidate beta-chain CDR3 sequences that are plausible as receptors while being directed toward that particular target, much as a language model conditioned on a topic generates relevant text.

Conditioning is the crucial trick. A generative model trained only on receptor sequences could produce endless plausible-looking CDR3 loops, but with no guarantee that any of them would recognize the intended target. By feeding epitope information into the generation process, the researchers steered the model so that its outputs were biased toward receptors relevant to a defined peptide-HLA context. This epitope-conditioned generation transforms the model from a random sequence generator into a targeted design tool, capable of expanding and prioritizing candidate receptors for downstream experimental screening in defined peptide-HLA and TCR-chain contexts, as the authors describe in their conclusions.

To demonstrate the capability, the team put the model through a concrete test. They selected five epitopes for which natural TCRs are already known, and asked ERTransformer to generate 1,000 candidate beta-chain CDR3 sequences for each one. The resulting pool of 5,000 artificial sequences was then analyzed for how well it satisfied the statistical expectations of real receptor biology. The generated candidates showed low sequence similarity to natural TCR beta chains, meaning the model was not simply memorizing and copying receptors from its training data, while at the same time retaining plausible CDR3 lengths, realistic amino-acid composition, and the conservative substitution patterns characteristic of genuine receptor loops. In other words, the artificial sequences looked novel but not alien, a balance that is notoriously hard to strike in generative protein design.

Novelty alone, however, proves nothing in immunology. A receptor sequence that looks plausible on paper may fail to fold, fail to bind, or bind the wrong things entirely. That is why the most striking part of the study is its wet-laboratory validation. The researchers selected a subset of the artificial TCRs and tested them experimentally using flow cytometry in defined TCR and peptide-HLA contexts, measuring the degree of T-cell activation each engineered receptor produced. The results exceeded what many in the field might have expected: the level of T-cell activation induced by the selected artificial receptors was either comparable to or even surpassed that of the natural receptors specific for the same epitopes. Synthetic sequences, dreamed up by a transformer model and never evolved in any organism’s thymus, could genuinely do the job.

The implications of that finding ripple across several areas of medicine. TCR-based immunotherapies, in which a patient’s T cells are engineered to express a receptor targeting a tumor-associated peptide, represent one of the most promising frontiers in cancer treatment. But their development has been constrained by the difficulty of sourcing high-affinity, specific receptors, particularly for targets where natural T cells respond weakly or not at all. A generative model that can propose thousands of candidate receptors for a defined target, each statistically vetted for plausibility, could dramatically expand the starting pool for screening and increase the odds of finding a receptor with the right combination of potency and specificity. The authors position ERTransformer explicitly as a tool to expand and prioritize candidates for downstream experimental screening, not as a replacement for experimentation, but as a way to make that experimentation far more efficient.

The study also illustrates a broader trend in computational biology: the power of pre-training on massive unlabeled datasets before fine-tuning on specific tasks. Just as language models learn general grammar from billions of sentences before being adapted to translation or summarization, EpitopeBERT and ReceptorBERT learned the general statistics of epitopes and receptors from millions of sequences before being combined for epitope-conditioned generation. The supplementary analyses accompanying the paper, including leakage-controlled evaluations, length distribution comparisons, and diversity and novelty analyses, suggest the team took seriously the methodological pitfalls that can make generative models appear better than they are, such as accidentally training on sequences that also appear in the test set.

Published as open access on 2 September 2026 in Genome Biology, with the work supported in part by the National Natural Science Foundation of China, the study arrives at a moment when generative artificial intelligence is reshaping protein science at large. From protein structure prediction to de novo enzyme design, machine learning models are increasingly proposing molecules that experimenters then confirm in the lab. The ERTransformer extends that paradigm to the adaptive immune system, one of the most complex and personalized molecular landscapes in biology. If the approach generalizes beyond the five epitopes tested here, the painstaking hunt for therapeutic T-cell receptors could become a collaboration between vast pre-trained models and targeted experiments, with algorithms proposing and laboratories verifying. For patients waiting on the next generation of engineered T-cell therapies, that collaboration could mean the difference between candidates found by chance and candidates found by design.

Subject of Research: Epitope-conditioned generative AI for designing T-cell receptor beta-chain CDR3 sequences for immunotherapy

Article Title: Epitope-conditioned generation of T-cell receptor β-chain CDR3 candidates using a pre-trained transformer model

Article References: Yang, J., He, B., Guan, L., Chen, S., Zhao, Y., Jiang, F., Wang, Z., Guo, Y., Xu, Z., Yuan, B., Song, J., Zhang, Q., Li, T., & Yao, J. (2026). Epitope-conditioned generation of T-cell receptor β-chain CDR3 candidates using a pre-trained transformer model. Genome Biology. https://doi.org/10.1186/s13059-026-04266-w

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04266-w

Keywords: T-cell receptor, CDR3, epitope, transformer model, generative AI, immunotherapy, peptide-HLA, protein design, flow cytometry, pre-trained language model, Genome Biology, T-cell activation